- Home
- LPTX vs VGI Comparison
LPTX vs VGI Comparison
Compare LPTX & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- VGI
- Stock Information
- Founded
- LPTX 2011
- VGI 2012
- Country
- LPTX United States
- VGI United States
- Employees
- LPTX N/A
- VGI N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- VGI Investment Managers
- Sector
- LPTX Health Care
- VGI Finance
- Exchange
- LPTX Nasdaq
- VGI Nasdaq
- Market Cap
- LPTX 119.6M
- VGI N/A
- IPO Year
- LPTX N/A
- VGI N/A
- Fundamental
- Price
- LPTX $0.33
- VGI $7.80
- Analyst Decision
- LPTX Hold
- VGI
- Analyst Count
- LPTX 1
- VGI 0
- Target Price
- LPTX N/A
- VGI N/A
- AVG Volume (30 Days)
- LPTX 3.3M
- VGI 46.0K
- Earning Date
- LPTX 08-11-2025
- VGI 01-01-0001
- Dividend Yield
- LPTX N/A
- VGI 12.66%
- EPS Growth
- LPTX N/A
- VGI N/A
- EPS
- LPTX N/A
- VGI N/A
- Revenue
- LPTX N/A
- VGI N/A
- Revenue This Year
- LPTX N/A
- VGI N/A
- Revenue Next Year
- LPTX N/A
- VGI N/A
- P/E Ratio
- LPTX N/A
- VGI N/A
- Revenue Growth
- LPTX N/A
- VGI N/A
- 52 Week Low
- LPTX $0.22
- VGI $6.68
- 52 Week High
- LPTX $4.79
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- LPTX 48.69
- VGI 51.62
- Support Level
- LPTX $0.28
- VGI $7.82
- Resistance Level
- LPTX $0.36
- VGI $7.93
- Average True Range (ATR)
- LPTX 0.04
- VGI 0.06
- MACD
- LPTX 0.01
- VGI -0.00
- Stochastic Oscillator
- LPTX 39.43
- VGI 39.29
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .